Thromboembolism during estrogen therapy of prostatic cancer. Report on two cases.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000328:Adult; D000367:Age Factors; D000368:Aged; D000924:Anticholesteremic Agents; D000925:Anticoagulants / Q000627:therapeutic use; D001779:Blood Coagulation Factors; D001786:Blood Glucose; D001792:Blood Platelets / Q000201:enzymology; D002277:Carcinoma / Q000188:drug therapy*; D002319:Cardiovascular System / Q000503:physiopathology; D002369:Castration; D003276:Contraceptives, Oral / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D007866:Leg / Q000098:blood supply; D008055:Lipids / Q000097:blood; D008099:Liver / Q000503:physiopathology; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D010690:Phlebography; D010713:Phosphatidylcholines / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013923:Thromboembolism / Q000139:chemically induced* / Q000401:mortality; D013924:Thrombophlebitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D001779:Blood Coagulation Factors; D001786:Blood Glucose; D003276:Contraceptives, Oral; D004967:Estrogens; D008055:Lipids; D010713:Phosphatidylcholines; D000251:Adenosine Triphosphatases; D008525:Medroxyprogesterone